CD8A and plasma cell myeloma: In the multiple myeloma xenograft tumor model in SCID CB17 mice the adaptive parts of immunity such as T cells are missing to support anti-tumor efficacy upon SOT101 treatment as SOT101 also efficiently stimulates effector and memory cytotoxic CD8+ T cells in vivo (12).